• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

COVID-19 Inpatient Admission Could Cost More Than $20,000 Per Patient

Article

Out-of-pocket expenses could be as high as $1,300.

The average cost of an inpatient admission for COVID-19 could exceed $20,000, according to the Peterson Center on Healthcare and the Kaiser Family Foundation. The Peterson-Kaiser researchers also estimated that the average out-of-pocket expense for patients with employer coverage could be $1,300, and that perhaps one in five people could face a “surprise” out-of-network bill.

These are estimates, not actual figures, and the researchers used pneumonia as a proxy for COVID-19. It is too early say what the actual costs associated with COVID-19 inpatient admissions will be. 

The Peterson-Kaiser researchers arrived at these estimate by using a sample of inpatient pneumonia cases drawn from an IBM MarketScan database that includes 18 million Americans enrolled in health plans offered by large employers in 2018. They sifted through the claims for DRGs for pneumonia, with and without complications. More specifically, they zeroed in on DRGs 193 (“simple pneumonia and pleurisy with major complications"), 194 (cases with “complication and comorbidity”) and 195 (cases without complications).

They found that average total cost of treatment for an inpatient admission for pneumonia with major complications was $20,292; an admission with [not major] complications and comorbidity, $13,767; and without complications, $9,763.

As is typical with hospital costs and claims, the range across the country was large, from $11,533 (the 25th percentile ) to $24,178 (the 75th percentile).

The out-of-pocket costs were actually a bit lower for patients with major complications ($1,300) than those without complications ($1,464). People with complications or comorbidity may reach their deductible faster because of prior expenses, so the out-of-pocket expense tied to the pneumonia episode might be lower. Last week, many insurers have moved to waive out-of-pocket costs associated with testing for the presence of the SARS-CoV-2, the virus that causes COVID-19. But OOP for treatment is a different matter.

Surprise billing has been a hot topic, and there is bipartisan agreement in Washington about curbing the practice, although not necessarily agreement on legislation that would do so. The Kaiser researchers also found that 18% of patients with an in-network admission for pneumonia with major complications or comorbidities faced an out-of-network charge of some kind. 

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.